

Mara Ten Kate

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6362945/publications.pdf>

Version: 2024-02-01

78
papers

1,281
citations

411340

20
h-index

445137

33
g-index

84
all docs

84
docs citations

84
times ranked

2333
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2023, 19, 807-820.	0.4	4
2	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. <i>Molecular Psychiatry</i> , 2022, 27, 1990-1999.	4.1	9
3	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 840651.	1.7	20
4	Regional associations of white matter hyperintensities and early cortical amyloid pathology. <i>Brain Communications</i> , 2022, 4, .	1.5	9
5	Longitudinal retinal layer changes in preclinical Alzheimer's disease. <i>Acta Ophthalmologica</i> , 2021, 99, 538-544.	0.6	13
6	What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021, 76, 1499-1511.	2.4	14
7	Are Apathy and Depressive Symptoms Related to Vascular White Matter Hyperintensities in Severe Late Life Depression?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, 34, 21-28.	1.2	12
8	Amyloid- β , cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 348-358.	1.7	9
9	White matter microstructure disruption in early stage amyloid pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12124.	1.2	16
10	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464.	0.4	13
11	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. <i>Annals of Neurology</i> , 2021, 89, 987-1000.	2.8	20
12	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. <i>Brain Communications</i> , 2021, 3, fcab201.	1.5	14
13	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. <i>Biomedicines</i> , 2021, 9, 1610.	1.4	7
14	Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60-102 Years. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1609-1617.	1.7	7
15	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	1.2	7
16	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020, 16, e036954.	0.4	1
17	Amyloid- β deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e040991.	0.4	0
18	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e042739.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Amyloid β^2 deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e042768.	0.4	0
20	Data-assisted differential diagnosis of dementia by deep neural networks using MRI: A study from the European DLB consortium. <i>Alzheimer's and Dementia</i> , 2020, 16, e043593.	0.4	1
21	Ocular biomarkers for cognitive impairment in nonagenarians; a prospective cross-sectional study. <i>BMC Geriatrics</i> , 2020, 20, 155.	1.1	8
22	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.	1.2	13
23	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020, 143, 3776-3792.	3.7	89
24	Retinal thickness as a potential biomarker in patients with amyloid-proven early and late-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 463-471.	1.2	25
25	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.4	46
26	Retinal layer thickness in preclinical Alzheimer's disease. <i>Acta Ophthalmologica</i> , 2019, 97, 798-804.	0.6	36
27	Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. <i>Neurobiology of Aging</i> , 2019, 77, 58-65.	1.5	14
28	A metabolite-based machine learning approach to diagnose Alzheimer's-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938.	1.8	70
29	Assessing Amyloid Pathology in Cognitively Normal Subjects Using ¹⁸ F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. <i>Journal of Nuclear Medicine</i> , 2019, 60, 541-547.	2.8	47
30	White matter hyperintensities and vascular risk factors in monozygotic twins. <i>Neurobiology of Aging</i> , 2018, 66, 40-48.	1.5	20
31	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 61, 75-81.	1.5	52
32	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2018, 61, 198-206.	1.5	44
33	ICP066: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. <i>Alzheimer's and Dementia</i> , 2018, 14, P59.	0.4	0
34	P1418: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. <i>Alzheimer's and Dementia</i> , 2018, 14, P465.	0.4	0
35	P1525: AMYLOID AGGREGATION IS ASSOCIATED WITH DECLINE ON DIGIT SPAN BACKWARD IN COGNITIVELY NORMAL ELDERLY MONOZYGOTIC TWINS. <i>Alzheimer's and Dementia</i> , 2018, 14, P533.	0.4	0
36	P3445: FACTORS PREDICTING MORTALITY AT THE MEMORY CLINIC AT SIRIRAJ HOSPITAL: 815 THAI COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1286.	0.4	0

#	ARTICLE	IF	CITATIONS
37	O5â€01â€03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NONâ€NEGATIVE MATRIX FACTORIZATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P1638.	0.4	0
38	ICâ€Pâ€005: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [¹⁸ F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMIâ€QUANTITATIVE AND QUANTITATIVE METHODS. <i>Alzheimer's and Dementia</i> , 2018, 14, P16.	0.4	0
39	P3â€355: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [¹⁸ F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMIâ€QUANTITATIVE AND QUANTITATIVE METHODS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1221.	0.4	0
40	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 100.	3.0	64
41	Secondary prevention of Alzheimerâ€™s dementia: neuroimaging contributions. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 112.	3.0	46
42	P2â€458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P895.	0.4	0
43	F1â€02â€03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P202.	0.4	0
44	Atrophy subtypes in prodromal Alzheimerâ€™s disease are associated with cognitive decline. <i>Brain</i> , 2018, 141, 3443-3456.	3.7	102
45	Retinal and Cerebral Microvasculopathy: Relationships and Their Genetic Contributions. , 2018, 59, 5025.		15
46	The EMIF-AD PreclinAD study: study design and baseline cohort overview. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 75.	3.0	48
47	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 64.	3.0	62
48	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 67.	1.7	29
49	Functional brain network centrality is related to APOE genotype in cognitively normal elderly. <i>Brain and Behavior</i> , 2018, 8, e01080.	1.0	18
50	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. <i>Journal of Psychiatric Research</i> , 2018, 104, 183-191.	1.5	21
51	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 167-182.e1.	1.5	60
52	Early- and Late-Onset Depression in Late Life: A Prospective Study on Clinical and Structural Brain Characteristics and Response to Electroconvulsive Therapy. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 178-189.	0.6	59
53	[P2â€399]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. <i>Alzheimer's and Dementia</i> , 2017, 13, P783.	0.4	0
54	[P4â€226]: BEST COMBINATORIAL LOWâ€COST MARKERS TO PREDICT MCI CONVERSION: AN EMIFâ€AD FEDERATION STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1356.	0.4	0

#	ARTICLE	IF	CITATIONS
55	[ICâ€Pâ€036]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P32.	0.4	0
56	[ICâ€Pâ€053]: EARLY ALTERATIONS IN RESTINGâ€STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P43.	0.4	0
57	[ICâ€Pâ€058]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P47.	0.4	0
58	[ICâ€Pâ€065]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P53.	0.4	0
59	[P1â€404]: EARLY ALTERATIONS IN RESTINGâ€STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P429.	0.4	0
60	[P1â€411]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P433.	0.4	0
61	[O2â€05â€01]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P559.	0.4	0
62	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimer's Research and Therapy, 2017, 9, 73.	3.0	25
63	IC-03-02: Grey Matter Connectivity is Associated with Clinical Progression in Non-Demented, Amyloid Positive Patients. , 2016, 12, P9-P10.		0
64	P2-167: Roadmap to the Biomarker-Based Diagnosis of Alzheimer's Disease. , 2016, 12, P679-P680.		0
65	O3â€08â€01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status. Alzheimer's and Dementia, 2016, 12, P303.	0.4	0
66	ICâ€Pâ€002: : Roadmap to The Biomarkerâ€Based Diagnosis of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P13.	0.4	0
67	ICâ€Pâ€017: Concordance of [18F]Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs. Alzheimer's and Dementia, 2016, 12, P23.	0.4	0
68	IC-02-04: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P7-P8.		0
69	P1â€284: Grey Matter Connectivity is Associated With Clinical Progression in Nonâ€Demented, Amyloid Positive Patients. Alzheimer's and Dementia, 2016, 12, P528.	0.4	0
70	P2-237: Concordance of [18F] Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P714-P715.		0
71	ICâ€Pâ€147: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P109.	0.4	0
72	P3â€269: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. Alzheimer's and Dementia, 2016, 12, P935.	0.4	0

#	ARTICLE	IF	CITATIONS
73	P4â€146: Largeâ€Vessel Disease and [18F]Flutemetamolâ€Amyloid Deposition in Cognitively Healthy Elderly Twins. Alzheimer's and Dementia, 2016, 12, P1069.	0.4	0
74	O4â€02â€04: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P335.	0.4	0
75	Impact of APOE-É4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. Neurobiology of Aging, 2016, 38, 14-20.	1.5	37
76	Gray matter network disruptions and amyloid beta in cognitively normal adults. Neurobiology of Aging, 2016, 37, 154-160.	1.5	51
77	IC-P-108: Impact of ApoE-Æ4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. , 2015, 11, P73-P73.		0
78	O2-09-01: Impact of ApoE-É4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. , 2015, 11, P194-P194.		0